Gustave Roussy, Cancer Campus, Grand Paris — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Gustave Roussy, Cancer Campus, Grand Paris appears in 77 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials77

Recruiting shown15

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of CancerNCT07436312 · lead sponsor · 2026-05-04

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/ResistanceNCT07483983 · lead sponsor · 2026-03-25

Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsNCT06907095 · lead sponsor · 2026-03-16

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerNCT07001618 · lead sponsor · 2025-11-17

A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast CancerNCT07159451 · lead sponsor · 2025-10-06

First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.NCT06840782 · lead sponsor · 2025-09-09

A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast CancerNCT06781996 · lead sponsor · 2025-09-09

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)NCT07016230 · lead sponsor · 2025-07-02

tislelizUMaB in canceR Patients With molEcuLar residuaL DiseaseNCT06332274 · lead sponsor · 2025-04-16

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast CancerNCT06508216 · lead sponsor · 2024-07-05

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXdNCT06298084 · lead sponsor · 2024-03-21

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority StudyNCT05692999 · lead sponsor · 2023-03-20

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12CNCT05631249 · lead sponsor · 2022-12-13

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast CancerNCT04965766 · lead sponsor · 2021-05-11

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate CancerNCT03819101 · lead sponsor · 2019-06-06

Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic DiseasesNCT07544225 · lead sponsor · 2026-12-01

NOT_YET_RECRUITING

Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.NCT07802847 · lead sponsor · 2026-09-01

NOT_YET_RECRUITING

Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate CancerNCT07591467 · lead sponsor · 2026-09-01

NOT_YET_RECRUITING

Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast CancerNCT06787118 · lead sponsor · 2025-12-01

NOT_YET_RECRUITING

Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid StructuresNCT06713798 · lead sponsor · 2025-01-30

Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyNCT05180006 · lead sponsor · 2022-02-24

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)NCT05215106 · lead sponsor · 2021-12-06

ACTIVE_NOT_RECRUITING

Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung CancerNCT04940325 · lead sponsor · 2021-05-12

ACTIVE_NOT_RECRUITING

Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid TumorsNCT03982173 · lead sponsor · 2020-09-01

Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast CancerNCT04304924 · lead sponsor · 2020-06-17

Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer PatientsNCT04341207 · lead sponsor · 2020-04-03

A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate CancerNCT03314324 · lead sponsor · 2017-11-29

Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot StudyNCT03606070 · lead sponsor · 2017-11-25

A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic CancerNCT03212469 · lead sponsor · 2017-06-20

Axillary Reverse Mapping Using Near-infrared Imaging in Invasive Breast Cancer: Predictors of Nodal PositivityNCT02994225 · lead sponsor · 2017-03-10

Atezolizumab as Induction Therapy in Non-small Cell Lung CancerNCT02994576 · lead sponsor · 2016-12-12

Feasibility of Breast Cancer Risk Evaluation in Women From the General PopulationNCT02997384 · lead sponsor · 2016-12-01

Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic TumoursNCT02992912 · lead sponsor · 2016-11-15

Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer PatientsNCT02831530 · lead sponsor · 2016-03-16

Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung CancerNCT02679963 · lead sponsor · 2016-02-05

Robot Assisted Mastectomy Via Axillary Way With Areola Conservation and Immediate ReconstructionNCT02673268 · lead sponsor · 2015-11-25

Study to Validate a Model of Surgical Deescalation in Atypicals Breast LesionsNCT02523612 · lead sponsor · 2015-06-24

Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate CancerNCT02044354 · lead sponsor · 2014-05-22

Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast CancerNCT02089100 · lead sponsor · 2014-02-26

ACTIVE_NOT_RECRUITING

Randomized Phase II Study to Assess PD 0332991 in Breast CancerNCT02008734 · lead sponsor · 2014-01-01

Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC PatientsNCT02040064 · lead sponsor · 2014-01-01

Identification of Early Markers of Response and Resistance to TrastuzumabNCT01834950 · lead sponsor · 2013-03-27

Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening ProgramNCT01786031 · lead sponsor · 2012-12-01

Local Treatment by Thermic Destruction of Primitive Breast CancerNCT01706016 · lead sponsor · 2012-10-09

Evaluation of Beauty Care Before Chemotherapy in Women With Breast CancerNCT01459003 · lead sponsor · 2011-10-01

Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound ContrastNCT02666690 · lead sponsor · 2011-07-01

Functional Magnetic Resonance Imaging for High Throughput Curietherapy Planning in Prostate CancerNCT02516995 · lead sponsor · 2010-08-01

Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived ExosomesNCT01159288 · lead sponsor · 2010-05-19

Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast CancerNCT01112254 · lead sponsor · 2010-02-01

Identification of Marker of Primary or Acquired Resistance to Anti Tumorous TreatmentNCT02105168 · lead sponsor · 2009-07-01

Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast CancerNCT01180335 · lead sponsor · 2009-01-01

Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung CancerNCT01167530 · lead sponsor · 2008-02-26

Image Guided Radiation Therapy For Prostate CancerNCT00433706 · lead sponsor · 2007-06-01

Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by SurgeryNCT00410683 · lead sponsor · 2007-02-01

A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung CancerNCT00346645 · lead sponsor · 2006-06-01

Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer PatientsNCT00127088 · lead sponsor · 2004-10-01

Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate CancerNCT00126230 · lead sponsor · 2004-01-01

Radiofrequency Ablation of Lung TumorsNCT00180856 · lead sponsor · 2002-01-01

Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete RemissionNCT00005062 · lead sponsor · 1999-09-01

Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung CancerNCT00002823 · lead sponsor · 1995-02-01

Drugs studied in this sponsor's trials

44 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Gustave Roussy, Cancer Campus, Grand Paris as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

durvalumab4

cisplatin3

docetaxel3

placebo3

tremelimumab3

bevacizumab2

etoposide2

olaparib2

durvalumab RxCUI 1919503 · Lead sponsor in 4 linked trial(s) · 1 currently recruiting 4 trials cisplatin RxCUI 2555 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting 3 trials docetaxel RxCUI 72962 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting 3 trials placebo RxCUI 8375 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting 3 trials tremelimumab RxCUI 2619313 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials bevacizumab RxCUI 253337 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials etoposide RxCUI 4179 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials olaparib RxCUI 1597582 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials abemaciclib RxCUI 1946825 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial anastrozole RxCUI 84857 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial aspirin RxCUI 1191 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial atezolizumab RxCUI 1792776 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial atezolizumab Injection RxCUI 1792779 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial atorvastatin RxCUI 83367 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial azithromycin RxCUI 18631 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial carboplatin RxCUI 40048 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial cemiplimab RxCUI 2058826 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial cyclophosphamide RxCUI 3002 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial doxorubicin hydrochloride RxCUI 142433 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial elacestrant RxCUI 2628469 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial enzalutamide RxCUI 1307298 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial epirubicin RxCUI 3995 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial everolimus RxCUI 141704 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial exemestane RxCUI 258494 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial

Sponsor roles

lead sponsor61

collaborator16

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.